Navigation Links
Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
Date:10/22/2008

nts

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to receive regulatory approval for its drug candidates, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners


'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
4. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
5. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
6. ThreeWire Expands Presence in the Pharmaceutical Arena
7. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
8. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
9. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
11. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Biotech Ltd. (Nasdaq: SVA ), a leading provider ... today announced that it will release its unaudited financial ... after market close on Wednesday, August 12, 2015. The Company ... 2015, at 8:00 a.m. EDT (Thursday, August 13, 2015 ... Company,s financial results and provide an update on recent ...
(Date:8/3/2015)... GREENVILLE, N.C. , Aug. 3, 2015 /PRNewswire/ ... will unveil its new Fingerprint Molecular Identification™ (FMID) ... Identification,s educational conference in Sacramento, Calif. ... in forensic science, will enable law enforcement agents, ... molecular profile of criminal suspects. By ...
(Date:8/3/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic and Dental sectors of healthcare, announced today that ... Canaccord|Genuity Growth Conference in Boston, Massachusetts ... William C. Taylor , President and COO, and ...
(Date:8/3/2015)... WESTWOOD, Mass. , Aug. 3, 2015  Merck ... company for innovative and top-quality high-tech products in the ... together with the US-based company Nano-C, their development and ... field of organic photovoltaics (OPV). Merck KGaA, Darmstadt, ... participate in the growing OPV sector. Novel ...
Breaking Biology Technology:Sinovac to Host Conference Call to Report Second Quarter 2015 Unaudited Financial Results 2ArroGen Previews New Fingerprint Molecular Identification Technology 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4
... (Nasdaq: KNDL ) ("Kendle"), announced today that ... cash tender offer and consent solicitation for any and ... outstanding 3.375% Convertible Senior Notes due 2012 (CUSIP No. ... each $1,000.00 principal amount of Notes validly tendered and ...
... 2011 K-V Pharmaceutical Company (NYSE:  KVa/KVb) announced today ... divest Nesher Pharmaceuticals, Inc., its generics subsidiary, and the ... Inc. for approximately $60 million in cash. The transaction ... KV,s 2012 fiscal year, subject to customary closing conditions. ...
... for cell-based diagnostics and regenerative medicine therapies. However, being ... desired cell type -- such as muscle, skin, blood ... of these technologies. New research presented on June ... Society for Stem Cell Research (ISSCR) shows that systematically ...
Cached Biology Technology:Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 2Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 3Kendle International Inc. Increases Consideration Amount for Tender Offer and Consent Solicitation for Convertible Notes 4K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 2K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 3K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 4K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 5K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 6K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 7Researchers engineer the environment for stem cell development to control differentiation 2Researchers engineer the environment for stem cell development to control differentiation 3
(Date:7/27/2015)... 27, 2015   Zynx Health ™, the ... improvement solutions, today announced that its ZynxCarebook ... on Android smartphones and tablets. With this expansion, ... can use ZynxCarebook to securely exchange messages and ... care transitions to other care settings, and improve ...
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/188684 for BEHAVIORAL-DIRECTED ... another new convenient and secure method to make ... innovative payment methods, introduced with its groundbreaking voice-direct ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... Ont., June 21, 2011Researchers at St. Michael,s Hospital have found ... with kidney failure. Cells that help protect blood vessels ... the night than those who undergo standard daytime dialysis in ... This is important for patients with kidney failure, which ...
... Cervical ripening that instigates preterm labor is distinct ... labor, researchers at UT Southwestern Medical Center have found. ... cervical ripening and remodeling is likely just an accelerated ... term ripening is caused primarily by activation of inflammatory ...
... perception that bigger, stronger, faster organisms have a distinct ... in a given community. But new research from ... communities, organisms increase their chances of survival if they ... survive as well, a sort of "survival of the ...
Cached Biology News:New evidence of the benefits of home dialysis for kidney patients 2Researchers find process of cervical ripening differs between term and preterm birth 2Bacteria develop restraint for survival in a rock-paper-scissors community 2
... are well-characterized tissue-specific stem cells that exhibit ... the life-long maintenance of the hematopoietic system. ... adult bone marrow where hematopoiesis is continuously ... in cord blood, fetal liver, adult spleen ...
Anti-TWIK-1 Immunogen: Purified peptide from amino acids 53-69 of human TWIK-1 (Accession number O00180)....
EDG-6 (1)...
RAW; Collected from 8-12 week old sexually mature mice that are free of common parasites; RAW Collected from 8-12 week old sexually mature mice that are free of common parasites....
Biology Products: